UnitedHealthcare IMRT Coverage Update

Coverage Criteria for IMRT

Proven/Medically Necessary Indications

IMRT is considered proven and medically necessary for definitive therapy of the following when ALL listed apply (site-specific details follow):

Proven Indications list: IMRT for definitive therapy of: anus/anal canal cancer; breast cancer when left-sided internal mammary nodes are treated or for accelerated partial breast irradiation up to 5 fractions; central nervous system (CNS) tumors (primary or benign) including brain, brainstem, and spinal cord; cervical cancer; endometrial cancer; esophageal cancer; head and neck cancers (including lymphoma and solitary plasmacytomas) when treatment includes pharynx (nasopharynx, oropharynx, hypopharynx), larynx (stage III or IV glottic), salivary glands, oral cavity (including tongue), nasal cavity, and paranasal sinuses; mediastinal tumors (e.g., lymphomas, thymomas), including tracheal cancer; non-small cell lung cancer, stage III, undergoing chemoradiation therapy; pancreatic cancer; prostate cancer; vulvar cancer; compensator-based beam modulation treatment when used in combination with a proven IMRT indication; hippocampal-avoidance whole brain radiation therapy (HA-WBRT) up to 10 fractions when all HA-WBRT-specific conditions are met (see HA-WBRT criteria).

Sites enumerated in policy chunks 3 and 4.

Exceptions / Case-by-case

Exception/Case-by-case coverage:

Case-by-case exceptions: IMRT may be covered for other conditions, including recurrences or metastases, when at least one of the following is present: 1) A clinically appropriate radiation dose is required and a non-IMRT technique would increase the probability of clinically meaningful normal tissue toxicity as demonstrated by a plan comparison (e.g., 3D-CRT vs IMRT using RTOG/QUANTEC OAR constraints); or 2) The same or an immediately adjacent area has been previously irradiated and sculpting of dose distribution is necessary to avoid exceeding cumulative normal tissue tolerance.

Requests evaluated on a case-by-case basis per policy instructions (chunk 4).

Unproven / Not Medically Necessary

Not medically necessary / unproven:

Unproven: IMRT used in conjunction with proton beam radiation therapy is considered unproven and not medically necessary due to insufficient evidence of efficacy.

Explicitly listed in policy (chunk 5).

Guideline recommendations

Professional society recommendations and rationale supporting IMRT use:

Guideline‑based preference: Multiple professional guidelines (ACR, ESMO, NCCN, ASTRO) recommend IMRT/VMAT or consider IMRT usually appropriate for specific cancer sites because it reduces dose to normal tissues and acute/late toxicity while maintaining local control.

Guideline rationale summarized from cited societies (chunks 20,21,22,34,35).

Anal cancer (DP‑IMRT) evidence

Anal cancer — trial evidence and implications:

RTOG 0529 outcomes: Dose‑painted IMRT (DP‑IMRT) with concurrent 5‑FU/MMC (RTOG 0529) demonstrated significant reductions in several acute toxicities (hematologic grade ≥2, grade ≥3 GI and dermatologic events) compared with historical controls; long‑term follow‑up showed similar efficacy to conventional radiation with decreased grade ≥3 late effects. The trial emphasized stage‑specific dose prescriptions and the importance of real‑time radiation quality assurance.

Trial details and long‑term outcomes from RTOG 0529 (chunks 18–19).

Breast cancer (APBI‑IMRT and whole breast IMRT)

Breast cancer — APBI‑IMRT and IMRT outcomes:

APBI‑IMRT RCT outcomes: A phase III randomized trial (n=520) of APBI‑IMRT (30 Gy in five fractions) versus whole‑breast irradiation found no significant difference in 10‑year ipsilateral breast tumor recurrence and reported significantly less acute and late toxicity with improved cosmesis and health‑related QOL for APBI‑IMRT. Phase II and observational studies report excellent local control and favorable cosmetic/toxicity profiles with APBI‑IMRT.

APBI‑IMRT trial and follow‑up documented in chunks 23,25,26.

CNS tumors

Central nervous system (CNS) tumors — IMRT outcomes and guideline stance:

CNS evidence and recommendations: Prospective and randomized studies and large institutional series report favorable volumetric responses, functional outcomes, and low rates of high‑grade late toxicity with IMRT; ASTRO strongly recommends IMRT/VMAT for IDH‑mutant grade 2/3 diffuse gliomas to reduce acute and late toxicity, and NCCN endorses conformal techniques for CNS tumors.

Evidence and guideline recommendations summarized from chunks 29–31,33,34,35.

Cervical cancer

Cervical cancer — comparative outcomes:

IMRT vs 3D‑CRT outcomes: Randomized and retrospective studies indicate IMRT reduces bowel dose and is associated with lower rates of acute grade ≥3 GI toxicity and fewer late severe GI/GU toxicities compared with 3D‑CRT, while overall survival and disease‑free survival are similar in reported cohorts; studies are limited by small size and single‑center designs.

Key studies and limitations are described in chunks 36 and 37.

Guideline concordant coverage criteria

Guideline-based preferred uses and rationale

Preferred settings for IMRT: IMRT is recommended or preferred for postoperative pelvic radiotherapy in cervical and endometrial cancer to decrease acute and chronic GI/GU toxicity; IMRT is preferred in definitive pelvic treatment when minimizing dose to bowel, bone marrow, and other OARs is important; IMRT or particle therapy may be used for esophageal cancers when OAR dose reduction is required.

Derived from ASTRO, ESGO/ESTRO/ESP, NCCN guideline statements (chunks 41,42,43,48,53).

IGRT requirement: Daily image guidance (orthogonal imaging and/or routine volumetric imaging such as cone‑beam CT) is strongly recommended with IMRT to ensure target coverage and normal tissue sparing, particularly in endometrial and pelvic treatments.

IGRT emphasized in guideline excerpts (chunks 42,48,43).

HA-WBRT with memantine — coverage-relevant clinical criteria

Covered when ALL of the following are met

HA-WBRT + memantine criteria: 1) Patient planned to receive whole‑brain radiotherapy for brain metastases; 2) No metastases in the hippocampal‑avoidance region documented on imaging (generally no lesions within ~5 mm of hippocampus); 3) Expected survival of four months or greater; 4) Adequate performance status (e.g., ECOG ≤2 or KPS ≥70); 5) Memantine administered per guideline recommendations when applicable.

Based on phase III randomized evidence (Brown et al., NRG CC001) and ASCO/SNO/ASTRO and NCCN guidance (chunks 72–74,69).

IMRT for head and neck cancers — coverage-relevant considerations

Considered appropriate when treatment planning demonstrates benefit in sparing critical organs at risk

Situations favoring IMRT: IMRT is preferred to reduce long‑term toxicity (e.g., xerostomia, dysphagia) for oropharyngeal, nasopharyngeal, nasal cavity, paranasal sinus, salivary gland, and select laryngeal/thyroid sites; when dose constraints to salivary glands, pharyngeal constrictors, temporal lobes, cochlea, optic structures, or other critical OARs can be meaningfully improved; for complex target geometries or bilateral neck irradiation where OAR sparing is important. Dysphagia‑optimized IMRT (DO‑IMRT) has shown improved patient‑reported swallowing outcomes versus standard IMRT in an RCT.

Supported by randomized trials and guideline recommendations (chunks 56,66,62,58).

Radiation dose considerations for extramedullary plasmacytoma

Coverage of dose regimens

Dose-response considerations: Local control and response rates for extramedullary plasmacytoma (EMP) vary with dose; both ≤45 Gy and >45 Gy regimens have been used with reported efficacy. Selection of dose should be individualized: lower doses (≤45 Gy) may be effective for primary EMP while higher doses (>45 Gy) may improve response in some subgroups; clinical judgment and comparative planning should guide dose selection.<=45 Gy vs >45 Gy

Retrospective data and guideline review summarized in chunk 59 and 62.

HA-WBRT (hippocampal avoidance) coverage

Covered when ALL of the following are met (HA-WBRT recommendation context):

HA-WBRT coverage criteria: 1) Patient planned to receive whole‑brain radiotherapy for brain metastases; 2) No metastases within the hippocampal‑avoidance region (commonly defined as within 5 mm of the hippocampus) documented on imaging; 3) Expected survival ≥ 4 months; 4) Memantine administered per guideline recommendation when applicable; 5) Adequate performance status (ECOG ≤2 or KPS ≥70); and 6) Absence of leptomeningeal disease.

Reflects randomized trial evidence (Brown et al.) and ASCO/SNO/ASTRO and NCCN recommendations (chunks 72–74).

Mediastinal tumors / Lymphoma

Covered when ALL of the following are met (mediastinal lymphoma / Hodgkin and select nodal disease):

IMRT for mediastinal tumors: 1) Indication is mediastinal lymphoma, thymoma, or other mediastinal tumor where sparing of heart, esophagus, spinal cord, and breasts is required to meet dose constraints; 2) Comparative planning shows IMRT achieves superior or equivalent PTV coverage while reducing high‑dose exposure to critical OARs compared with APPA/3D‑CRT; 3) Plan demonstrates adherence to recommended OAR dose constraints and includes justification for any increased low‑dose bath to normal tissues.

Supported by systematic review and guideline statements (chunks 75–77).

NSCLC stage III (definitive chemoradiation)

Covered when ALL of the following are met (locally advanced NSCLC, definitive chemoradiation):

IMRT for stage III NSCLC: 1) Patient has unresectable stage III NSCLC planned for definitive concurrent chemoradiation; 2) Treatment planning demonstrates IMRT achieves lower heart dose and/or reduced risk of high‑grade pneumonitis compared with 3D‑CRT or other justification for IMRT is documented; 3) Heart and lung dose constraints are specified and met, with attempts to minimize heart V40/V50 as clinically feasible.

Based on RTOG 0617 secondary analyses and NCCN guidance indicating reduced severe pneumonitis and lower heart dose with IMRT (chunks 79,80,85).

Pancreatic cancer

Covered when ALL of the following are met (pancreatic cancer):

IMRT for pancreatic cancer: 1) Indication is locally advanced or adjuvant pancreatic adenocarcinoma where IMRT is used to improve PTV coverage while reducing dose to stomach and duodenum; 2) Comparative planning shows IMRT reduces GI OAR doses compared with 3D‑CRT and meets institutional or national OAR constraints; 3) Intended fractionation and concurrent systemic therapy are documented.

Supported by retrospective series, systematic review, and ASTRO/NCCN guidance (chunks 86–90).

Thymic tumors and Prostate cancer

Covered when ALL of the following are met (thymic tumors and prostate cancer context):

IMRT for thymic and prostate cancers: 1) For thymomas/thymic carcinomas: IMRT is used when advanced techniques are required to deliver curative RT safely and to minimize cardiac dose; 2) For prostate cancer: IMRT is used per guideline and institutional protocols (including recommended photon energy ≥6 MV and daily IGRT when specified); 3) Treatment planning documents OAR sparing and adherence to relevant dose constraints and, when pelvic nodal irradiation is performed, nodal doses per guideline recommendations are used.

Supported by NCCN, AUA/ASTRO, and prospective/observational data (chunks 78,90,91,95,96).

Guideline-supported Indications

Clinical guideline–based support for IMRT use

Guideline-supported uses: Use of IMRT is supported by multiple professional societies (NCCN, ACR, AUA/ASTRO, ESGO) for prostate (all risk groups), pelvic nodal irradiation, vulvar cancer adjuvant therapy, and as an option in pancreatic adenocarcinoma to improve PTV coverage while reducing OAR dose.

Guideline references include NCCN, ACR, AUA/ASTRO, ESGO (chunks 90,95,96,97,101,102).

Clinical Evidence Summaries

Evidence summaries and outcomes supporting clinical use

Prostate evidence: Randomized and observational studies report that IMRT provides equivalent or improved disease control and reduced acute and late GI/GU toxicities compared with 3D‑CRT; long‑term data show acceptable tumor control and low rates of grade 3 toxicity at 10 years.

Includes long‑term cohort and randomized trial data (chunks 91–94).

Pancreas statement: Systematic reviews and guideline statements indicate IMRT/VMAT can improve PTV coverage and decrease OAR dose in pancreatic adenocarcinoma; evidence supports reduced GI toxicity with IMRT versus 3D‑CRT though OS and PFS differences are not consistent.

Summarized from chunks 86–90 and 89.

Vulvar evidence: Retrospective single‑center series report high response rates and acceptable toxicity with dose‑escalated IMRT (often with concurrent platinum) for locally advanced vulvar cancer; studies limited by retrospective design and small sample sizes.

Evidence summarized from chunks 98–102.

Intensity-Modulated Radiation Therapy (IMRT) — Definitive Therapy (revised indications)

Revisions to Coverage Rationale for IMRT for Definitive Therapy

Definitive Therapy indications updated: IMRT for Definitive Therapy for the primary site is proven and medically necessary for a revised list of conditions that now includes vulvar cancer and specifies anus/anal canal cancer (replacing the prior term 'anal cancer').

Operational policy revisions documented in policy history (chunk 119).

IMRT used in conjunction with proton beam radiation therapy is considered unproven and not medically necessary due to insufficient evidence of efficacy. The clinical literature reviewed did not identify supportive evidence for combining IMRT and proton-beam delivery in a single treatment plan.

Available trials and series cited throughout the policy often have methodologic limitations that affect interpretation of results, including small sample sizes, single‑center designs, heterogeneous treatment techniques, and limited long‑term functional or quality‑of‑life data. These limitations are noted in the referenced trials and systematic reviews and should be considered when applying study findings to coverage determinations.

Per NCCN guidance, IMRT should not be used as a routine alternative to brachytherapy for treatment of central disease in individuals with an intact cervix; brachytherapy remains the preferred local therapy for central cervical disease and IMRT substitution is discouraged.

Hippocampal‑avoidance whole‑brain radiotherapy (HA‑WBRT) is not appropriate when there are metastases within the hippocampal‑avoidance region. Guideline recommendations require documented absence of hippocampal lesions on imaging before HA‑WBRT is delivered.

Guideline statements note performance status is an important consideration for WBRT candidacy: HA‑WBRT is recommended for individuals with adequate expected survival (typically ≥4 months) and sufficient functional status. The guidance also specifies that patients with very poor performance status (e.g., KPS ≤ 50) or those with limited expected benefit from systemic therapy may not derive benefit from WBRT approaches.

The combined use of IMRT and proton beam radiation therapy in a single treatment plan is not supported by the evidence identified in the clinical literature. No studies were found that establish the safety or efficacy of integrating both modalities within one plan, and therefore such combination is not considered standard care.

IMRT in combination with proton beam therapy has insufficient evidence of efficacy and is therefore classified as not medically necessary in this policy.

A Cochrane evidence review and related CNS literature highlight uncertainty about optimal timing of radiotherapy for low‑grade gliomas; the review found insufficient evidence to determine whether early versus delayed RT is superior, underscoring that timing decisions for low‑grade gliomas remain inconclusive.

Alternative fractionation schedules such as SMART boost have limited randomized evidence. Available randomized and prospective data are insufficient to support routine use outside of clinical trials or specialized centers, and such approaches should generally be limited to research settings.

Randomized data in unresectable stage III NSCLC showed that a higher‑dose regimen of 74 Gy delivered with concurrent chemotherapy was not superior to standard‑dose (60 Gy) chemoradiation and may be harmful; therefore routine dose escalation to 74 Gy with concurrent chemotherapy is not supported.

The excerpted material does not contain the full list of conditions categorized as not medically necessary; the complete medical policy includes detailed Not Medically Necessary sections elsewhere. Coverage determinations should reference the full policy text for complete NMN criteria.

Provider Actions, Prior Authorization, and Documentation

Documentation Required

Coverage Determination and Documentation

No explicit coverage denial triggers are specified in the provided excerpts. However, coverage determinations remain subject to federal, state, and contractual requirements and availability of required documentation.

Benefit coverage is determined by federal, state, or contractual requirements; check state-specific policy versions where applicable.
Medical records documentation may be required to assess whether the member meets clinical criteria for coverage; submission of records does not guarantee payment.

Denial Risk

Potential Denial Conditions

Denial triggers may include insufficient or missing documentation and failure to meet applicable federal, state, or contractual requirements. If required medical records or justification for technique selection are not provided, coverage may be denied per plan rules.

Coding and Billing

IMRT-related CPT CodesCPT

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex.
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed.

Proton Delivery CPT CodesCPT

77520	Proton treatment delivery; simple, without compensation.
77522	Proton treatment delivery; simple, with compensation.
77523	Proton treatment delivery; intermediate.
77525	Proton treatment delivery; complex.

IMRT-related HCPCS G-CodesHCPCS

G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session.
G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session.
G6017	Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment.

Definitions and Key Terms

Definitive Therapy — Definition

DefinitionRadiation treatments for cancer with a curative intent.

Policy updateDefinition of 'Definitive Therapy' was revised in the policy (see Policy History).

Applies toAdults ≥19 years as specified in the policy scope.

Dose‑painted IMRT (DP‑IMRT)

DefinitionAn IMRT technique that prescribes different dose levels to subregions of the target (e.g., elective nodal volumes vs primary tumor) within the same treatment course.

Example trialRTOG 0529 evaluated DP‑IMRT for anal cancer with stage‑specified prescriptions and emphasized real‑time radiation QA.

Background and Clinical Evidence

Background: Intensity‑Modulated Radiation Therapy (IMRT) is an advanced, high‑precision external beam radiation technique that modulates beam intensity to conform dose to three‑dimensional tumor shapes while sparing adjacent normal tissues. IMRT is frequently used with image‑guided radiotherapy (IGRT) to ensure accurate target localization and delivery.

Guideline recommendations and evidence context — overlapping evidence

Guideline recommendations and evidence context — overlapping evidence base summarized:

Guideline and evidence overlap summary: Professional society guidelines (NCCN, ASTRO, ACR, ESMO, ESGO) and randomized, prospective, and retrospective studies collectively support IMRT use where dose conformity reduces OAR exposure and expected toxicity while maintaining local control; trial evidence (e.g., RTOG 0529, DO‑IMRT, NRG CC001) demonstrates reductions in acute/late toxicity or cognitive decline for appropriate indications. Limitations across the literature include small single‑center studies for some sites and heterogeneous comparators.

Synthesis drawn from chunks 20–22,28,34–37,56,72–77,79–80.

Clinical evidence summaries across multiple disease sites support clinical use of IMRT for indications including anal (dose‑painted IMRT in RTOG 0529), breast (APBI‑IMRT randomized trial showing comparable 10‑year local control with reduced toxicity), pancreatic (retrospective and guideline support for reduced GI toxicity), head & neck (randomized and cohort data supporting organ‑sparing benefits), prostate (long‑term observational and randomized data demonstrating reduced GI/GU toxicity), and gynecologic sites (reduced bowel/GU toxicity). Study limitations vary by disease site and include single‑center designs, heterogeneity in technique and fractionation, and limited long‑term QOL data in some series.

Revision History and Policy Changes

2025-10-01addedLatest

Added language that the Medical Policy does not apply to the states of Nebraska and North Carolina; refer to state-specific policy versions.

2025-06-01added

Added language that the Medical Policy does not apply to the states of Idaho and Kansas; refer to state-specific policy versions.

2025-06-01revised